Press Releases
TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting
December 11, 2011
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
December 5, 2011
TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development
June 8, 2011
TetraLogic Expands Series C Financing with New Investor Pfizer Ventures
September 27, 2010
TetraLogic Pharmaceuticals Initiates Phase 1 Clinical Trial of TL32711 In Patients with Refractory Solid Tumors or Lymphoma
January 8, 2010